TNF and cystoid macular edema: Finally, monoclonal antibodies with either anti-tumor necrosis factor-α or anti-vascular endothelial growth factor activity were administered to ten patients (9.6%) with AU refractory to previous immunosuppressive drugs and to three patients (2.9%) with retinal neovascularization and cystoid macular edema.